Hypercoagulability and tissue factor gene upregulation in hematologic malignancies

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 2, 2008, Pages 204-210

  Falanga, Anna ^a   Barbui, Tiziano ^a   Rickles, Frederick R ^b  

^a OSPEDALI RIUNITI   (Italy)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Acute promyelocytic leukemia; Essential thrombocythemia; Hypercoagulable state; Polycythemia vera; Tissue factor

Indexed keywords

CYTOKINE; PROCOAGULANT; THROMBOPLASTIN;

ACUTE LEUKEMIA; ARTICLE; BLOOD CLOTTING DISORDER; EXPERIMENTAL MODEL; GENE MUTATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; HEMATOLOGIC MALIGNANCY; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; LEUKEMIA CELL; MOLECULAR BIOLOGY; ONCOGENE; PATHOGENESIS; PATHOPHYSIOLOGY; PLATELET MICROPARTICLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPRESSOR GENE; STEM CELL; THROMBOCYTE AGGREGATION; TUMOR CELL; UPREGULATION;

HEMATOLOGIC NEOPLASMS; HEMOSTASIS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MYELOPROLIFERATIVE DISORDERS; NEOVASCULARIZATION, PATHOLOGIC; POLYCYTHEMIA VERA; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOPHILIA; THROMBOPLASTIN; UP-REGULATION;

EID: 48749127220     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-2008-1079262     Document Type: Article

References (44)

1. Barbui T, Finazzi G, Falanga A. The management of bleeding and thrombosis in acute leukemia and chronic myeloproliferative disorders. In: Henderson ES, Lister TA, Greaves MF, eds. Leukemia, 7th ed. Philadelphia, PA: Saunders; 2001:363-382
2. Falanga A, Rickles FR. Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003;16:463-482
3. Falanga A, Marchetti M. Thromboembolism in hematologic malignancies. In: Khorana AA, Francis CW, eds. Cancer-Associated Thrombosis. New York, NY: Informa Healthcare; 2008:131-149
4. Ziegler S, Sperr WR, Knobl P, et al. Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis. Thromb Res 2005;115: 59-64
5. De Stefano V, Sora F, Rossi E, et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost 2005;3: 1985-1992
6. Barbui T, Finazzi G. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk. Semin Thromb Hemost 2007;33:321-329
7. Schafer AI. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 2006;107:4214-4222
8. Michiels JJ, Berneman Z, Bockstaele DV, van der Planken M, De Raeve H, Schroyens W. Clinical and laboratory features, pathology of platelet-mediated thrombosis and bleeding complications and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost 2006;32:174-207
9. Dvorak HF, Rickles FR. Malignancy and hemostasis. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis, Basic Principles and Clinical Practice. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:851-873
10. Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 2001;102: V215-V224
11. Boccaccio C, Sabatino G, Medico E, et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005;434:396-400
12. Rong Y, Post DE, Pieper RO, et al. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 2005;65:1406-1413
13. Yu JL, May L, Lhotak V, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005;105: 1734-1741
14. Falanga A, Marchetti M, Vignoli A, et al. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte and plasma hemostatic and inflammatory molecules. Exp Hematol 2007;35:702-711
15. Tallman MS, Lefebvre P, Baine RM, et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost 2004;2:1341-1350
16. Falanga A, Iacoviello L, Evangelista V, et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocitic leukemia given all-trans-retinoic acid. Blood 1995;86:1072-1084
17. Dombret H, Scrobohaci ML, Daniel MT, et al. In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy. Leukemia 1995;9:19-24
18. Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000;96:4261-4266
19. Friedenberg WR, Roberts RC, David DE. Relationship of thrombohemorrhagic complications to endothelial cell function in patients with chronic myeloproliferative disorders. Am J Hematol 1992;40:283-289
20. Bellucci S, Ignatova E, Jaillet N, Boffa MC. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, tPA and vWF. Thromb Haemost 1993;70:736-742
21. Landolfi R, Ciabattoni G, Patrignani P, et al. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood 1992;80:1965-1971
22. Elliott MA, Tefferi A. Thrombosis and haemorrage in polycythemia vera and essential thrombocythemia. Br J Haematol 2005;128:275-290
23. Burgaleta C, Gonzalez N, Cesar J. Increased CD11/18 expression and altered metabolic activity in polymorphonuclear leukocytes from patients with polycythemia vera and essential thrombocythemia. Acta Haematol 2002;108:23-28
24. Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000;96:4261-4266
25. Kwaan HC, Wang J. Hyperviscosity in polycythemia vera and other red cell abnormalities. Semin Thromb Hemost 2003;29:451-458
26. Yedgar S, Koshkaryev A, Barshtein G. The red blood cell in vascular occlusion. Pathophysiol Haemost Thromb 2002;32: 263-268
27. Valles J, Santos MT, Aznar J, et al. Platelet-erythrocyte interactions enhance alpha (IIb)beta(3) integrin receptor activation and P-selectin expression during platelet recruitment: down-regulation by aspirin ex vivo. Blood 2002;99: 3978-3984
28. Pearson MJ, Lipowsky HH. Influence of erythrocyte aggregation on leukocyte margination in postcapillary venules of rat mesentery. Am J Physiol Heart Circ Physiol 2000; 279:M1460-1471
29. Jensen MK, de Nully Brown P, Lund BV, Nielsen O, Hasselbalch HC. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol 2000;110:116-124
30. Li N, Goodall AH, Hjemdahl P. A sensitive flow cytometric assay for circulating platelet-leukocyte aggregates. Br J Haematol 1997;99:808-816
31. Villmow T, Kemkes-Matthes B, Matzdorff AC. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes. Thromb Res 2002;108:139-145
32. Alvarez-Larràn A, Garcìa-Pagàn JC, Abraldes JG, et al. Increased CD11b neuthrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera. Br J Haematol 2004;124:329-335
33. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocytemia and polycythemia vera. Exp Hematol 2005; 33:523-530
34. Celi A, Pellegrini G, Lorenzet R, et al. P-selectin induces the expression of tissue factor on monocytes. Proc Nad Acad Sci U S A 1994;91:8767-8771
35. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR. A gain-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352: 1779-1790
36. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006;81:159-166
37. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005;366:1945-1953
38. Muller I, Klocke A, Alex M, et al. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J 2003;17:476-478
39. Falati S, Liu Q, Gross P, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003;197:1585-1598
40. Myers DD, Hawley AE, Farris DM, et al. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg 2003;38:1075-1089
41. Maugeri N, Giordano G, Petrilli MP, et al. Inibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug? J Thromb Haemost 2006;4:2593-2598
42. Shoji M, Hancock WW, Abe K, et al. Activation of coagulation and angiogenesis in cancer. Immunohistochemical localization in situ of clotting proteins and VEGF in human cancers. Am J Pathol 1998;152:399-411
43. Lyman GH, Khorana AA, Falanga A, et al. American society of clinical oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25:5490-5505
44. Kuderer NM, Khorana A, Lyman GH, Francis CW. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 2007;110:1149-1161